Literature DB >> 1372216

An overview of the role of calcium antagonists in the treatment of achalasia and diffuse oesophageal spasm.

T P Short1, E Thomas.   

Abstract

Early studies confirmed the beneficial effects of calcium channel blockers on the normal oesophagus, which included a decrease in lower oesophageal sphincter tone in achalasia and a decrease in oesophageal contractions and amplitude in diffuse oesophageal spasm. This resulted in the enthusiastic use of the drugs in both disorders. With further experience, and with increased recognition of side effects, the role of these drugs in the 2 disorders has been better clarified. Clinical trials in general have not reflected the improvement observed in the manometric parameters. Only a minority of patients appear to derive sustained symptomatic benefit. Calcium channel blockers may be the initial choice for high or moderate risk patients with achalasia prior to proceeding with pneumatic dilatation or surgical myotomy. In diffuse oesophageal spasm, they are a reasonable first choice for all risk categories.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372216     DOI: 10.2165/00003495-199243020-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  39 in total

Review 1.  Motor disorders of the esophagus.

Authors:  S Cohen
Journal:  N Engl J Med       Date:  1979-07-26       Impact factor: 91.245

2.  Efficacy of diltiazem in the treatment of diffuse oesophageal spasm.

Authors:  J P Drenth; L P Bos; L G Engels
Journal:  Aliment Pharmacol Ther       Date:  1990-08       Impact factor: 8.171

3.  Nifedipine in the treatment of diffuse oesophageal spasm.

Authors:  S M Nasrallah
Journal:  Lancet       Date:  1982-12-04       Impact factor: 79.321

4.  Comparison of effects of nifedipine, propantheline bromide, and the combination on esophageal motor function in normal volunteers.

Authors:  M Hongo; M Traube; R W McCallum
Journal:  Dig Dis Sci       Date:  1984-04       Impact factor: 3.199

5.  Nifedipine in the treatment of achalasia.

Authors:  K Berger; R W McCallum
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

6.  Clinical and manometric effects of nifedipine in patients with esophageal achalasia.

Authors:  M Bortolotti; G Labò
Journal:  Gastroenterology       Date:  1981-01       Impact factor: 22.682

Review 7.  Achalasia.

Authors:  J C Reynolds; H P Parkman
Journal:  Gastroenterol Clin North Am       Date:  1989-06       Impact factor: 3.806

8.  Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation.

Authors:  M Gelfond; P Rozen; T Gilat
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

Review 9.  Second-generation calcium antagonists: search for greater selectivity and versatility.

Authors:  B N Singh; S Baky; K Nademanee
Journal:  Am J Cardiol       Date:  1985-01-25       Impact factor: 2.778

10.  Effect of acute hypercalcemia on human esophageal motility.

Authors:  I C Danielides; M H Mellow
Journal:  Gastroenterology       Date:  1978-12       Impact factor: 22.682

View more
  3 in total

1.  Do calcium channel blockers and antimuscarinics protect against perforated colonic diverticular disease? A case control study.

Authors:  C R Morris; I M Harvey; W S L Stebbings; C T M Speakman; H J Kennedy; A R Hart
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

2.  SAGES guidelines for the surgical treatment of esophageal achalasia.

Authors:  Dimitrios Stefanidis; William Richardson; Timothy M Farrell; Geoffrey P Kohn; Vedra Augenstein; Robert D Fanelli
Journal:  Surg Endosc       Date:  2011-11-02       Impact factor: 4.584

3.  Descriptive Rules for Achalasia of the Esophagus, June 2012: 4th Edition.

Authors: 
Journal:  Esophagus       Date:  2017-09-05       Impact factor: 4.230

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.